Moderna and Merck’s positive Phase 3 INTerpath-001 results for their personalized mRNA neoantigen therapy intismeran autogene (mRNA-4157/V940) in resected high-risk melanoma, showing a 42% reduction in recurrence or death risk versus Keytruda alone at median 24.6 months follow-up, represent the main driver of trader sentiment. These data, released in detail around the October 2026 ESMO meeting after an August interim success, align with earlier Phase 2 durability signals and have prompted the companies to state they are engaging regulators while targeting a U.S. BLA submission and 2027 launch. Competitive positioning benefits from the individualized mRNA approach’s first-in-class late-stage validation, though personalized manufacturing scale-up and combination requirements with pembrolizumab remain key variables. No filing has been announced yet, leaving room for timing shifts ahead of the June 2027 market horizon.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato1H6H1D7D30DALL
View resolved

Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti